toddski
5 months ago
Company is expanding into compounded pet medications, real estate, and fintech. They appear to be diversifying into other / complimentary industries. This should bode well for continuing revenue and profit growth.
I have no idea how big the pet compounded medicine market is worth, thus no idea how to value that addition to the company.
The real estate / fintech company probably does less than 5m rev/year just based on reviewing their site.
Peaks orders are up well over 400% in the past couple months based on order #s. This part of the company is transitioning quite well into profit generation.
In all, the companies future appears bright, even with the FDA shutting down Tirzepatide compounding. The pet compounding market, if it works, could double or even triple quarterly revenues, especially if they partner with some larger veterinarians.
toddski
7 months ago
Although on paper, that look ridiculous, this is actually less than their previous contract. The previous contract was 31.5% of revenue. This is 30% of cash, meaning the cash after gross margin, SGA, etc. So with this contract it's a meaningful cut. Still too much in my opinion, but they are doing a great job at running the country and growing revs/profits.